QT/TdP Risk Screen


QT/TdP Risk Screen

A new early screening tool that helps to detect a compound’ proarrhythmic potential and to identify its safe concentration range


Clinically Validated

Validated on a set of 109 known drug compounds, 51 of which torsadogenic


Display and Export

Compounds lists can be uploaded and results can be downloaded in JSON or CSV format


Easy to Use

Well-designed wizard that guides through the setup of computation step by step

QT/TdP Risk Screen is based on simulations that estimate how a compound affects the electrophysiological properties of the Action Potential of isolated endocardial cells. Multiple channel−drug interactions and a state-of-the-art human ventricular Action Potential model (based on O’Hara et al. 2011) were used to perform more than 450,000 cellular simulations where the currents of the IKr (fast component delayed rectifier), IKs (slow component delayed rectifier), ICaL (L-type calcium) and INaL (late sodium) channels were blocked at different concentration levels.

The predictive performance of QT/TdP Risk Screen was evaluated by means of classifying the proarrhythmic risk of 109 known drug compounds, 51 of which torsadogenic (Llopis et al. 2020).

Research team

QT/TdP Risk Screen is the result of a collaboration among Universitat Politècnica de València (UPV, Valencia), Fundació Institut Hospital del Mar D’Investigacions Mèdiques (FIMIM, Barcelona), and InSilicoTrials Technologies

Articles & publications

Jordi Llopis, Julio Gomis-Tena, Jordi Cano, Lucia Romero, Javier Saiz, and Beatriz Trenor

Journal of Chemical Information and Modeling 2020 https://doi.org/10.1021/acs.jcim.0c00201

Lucia Romero, Jordi Cano, Julio Gomis-Tena, Beatriz Trenor, Ferran Sanz, Manuel Pastor, and Javier Saiz

Journal of Chemical Information and Modeling 58 (4), 867-878, 2018

Thomas O’Hara, Lászlo ́Virág, Andraás Varró, and Yoram Rudy

PLoS Computational Biology 7(5): e1002061, 2011

Start simulating now